Peripheral leukocyte microRNAs as novel biomarkers for COPD

Wang, Ruiying; Xu, Jianying; Liu, Hu; Zhao, Zhiping

doi:10.2147/copd.s130416

Cited by 28 publications

(18 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Finally, the combined expression of hsa-miR-195 and hsa-miR-143, obtained from databases, is able to identify lung cancer compared to disease-free status, but cannot distinguish COPD from lung cancer ( 176 ). From peripheral leucocytes, differential expression of miR-106b-5p, miR-183-5p, miR-125a-5p, and miR-100-5p was found in COPD compared to healthy controls, and miR-106b-5p was directly correlated with disease severity alleviation ( 88 ). Several studies have focused their interest on miRNAs from specific immune system cells exploring the implication of these structures in processes linked to asthma or COPD.…”

Section: Mirnas In Lung Diseasesmentioning

confidence: 99%

MicroRNAs as Potential Regulators of Immune Response Networks in Asthma and Chronic Obstructive Pulmonary Disease

et al. 2021

View full text Add to dashboard Cite

Chronic respiratory diseases (CRDs) are an important factor of morbidity and mortality, accounting for approximately 6% of total deaths worldwide. The main CRDs are asthma and chronic obstructive pulmonary disease (COPD). These complex diseases have different triggers including allergens, pollutants, tobacco smoke, and other risk factors. It is important to highlight that although CRDs are incurable, various forms of treatment improve shortness of breath and quality of life. The search for tools that can ensure accurate diagnosis and treatment is crucial. MicroRNAs (miRNAs) are small non-coding RNAs and have been described as promising diagnostic and therapeutic biomarkers for CRDs. They are implicated in multiple processes of asthma and COPD, regulating pathways associated with inflammation, thereby showing that miRNAs are critical regulators of the immune response. Indeed, miRNAs have been found to be deregulated in several biofluids (sputum, bronchoalveolar lavage, and serum) and in both structural lung and immune cells of patients in comparison to healthy subjects, showing their potential role as biomarkers. Also, miRNAs play a part in the development or termination of histopathological changes and comorbidities, revealing the complexity of miRNA regulation and opening up new treatment possibilities. Finally, miRNAs have been proposed as prognostic tools in response to both conventional and biologic treatments for asthma or COPD, and miRNA-based treatment has emerged as a potential approach for clinical intervention in these respiratory diseases; however, this field is still in development. The present review applies a systems biology approach to the understanding of miRNA regulatory networks in asthma and COPD, summarizing their roles in pathophysiology, diagnosis, and treatment.

show abstract

Section: Mirnas In Lung Diseasesmentioning

confidence: 99%

MicroRNAs as Potential Regulators of Immune Response Networks in Asthma and Chronic Obstructive Pulmonary Disease

et al. 2021

View full text Add to dashboard Cite

show abstract

“…From the results of the miRNA PCR array and replication cohort, we successfully identified miR‐15b‐5p as a novel biomarker for ACO. Several studies have described the difference in miRNA levels between patients with asthma or COPD and healthy controls 12‐15 . However, few studies have examined the difference in miRNA expression levels between ACO, asthma, and COPD.…”

Section: Discussionmentioning

confidence: 99%

Circulating microRNA‐15b‐5p as a biomarker for asthma‐COPD overlap

Hirai

Shirai

Shimoshikiryo

et al. 2020

Allergy

View full text Add to dashboard Cite

Background It remains unclear how to characterize different subtypes of asthma and chronic obstructive pulmonary disease (COPD). We previously described serum periostin and chitinase‐3‐like protein 1 (YKL‐40) as useful markers for asthma‐COPD overlap (ACO). MicroRNAs (miRNAs) are now recognized as markers for identifying the pathophysiological features in several diseases. This study aimed to identify circulating miRNAs that could discriminate patients with ACO from patients with asthma or COPD. Methods This study included two independent cohorts. First, we screened 84 miRNAs for expression levels in patients with ACO (n = 6) or asthma (n = 6) using a quantitative real‐time PCR array. The miRNAs showing at least a 2‐fold difference in the discovery phase were analyzed in 30 patients each with asthma, COPD, or ACO in the replication phase. The diagnostic accuracy was evaluated using the area under the receiver operating characteristic curve (AUROC). Results Nine miRNAs were identified in the discovery phase. Five of these miRNAs (miR‐148a‐3p, miR‐15b‐5p, miR‐223‐3p, miR‐23a‐3p, and miR‐26b‐5p) had lower levels in ACO patients and could discriminate between ACO patients and patients with either asthma or COPD. miR‐15b‐5p was the most accurate miRNA for the discrimination of patients with ACO (AUROC, 0.71). Moreover, the combined assessment of miR‐15b‐5p, serum periostin, and YKL‐40 (AUROC, 0.80) improved diagnostic accuracy for ACO compared with the combined model of periostin and YKL‐40 (AUROC, 0.69). Conclusions Circulating miR‐15b‐5p is a potential marker for identifying patients with ACO. By elucidating the molecular pathways controlled by miRNAs, we may better understand the pathophysiology of ACO.

show abstract

“…miRNAs are easily detectable due to their stability in serum as they are resistant to degradation and are highly detectable by quantitative PCR, microarrays and miRNA sequencing. W ang et al [ 101 ] found that miR-106b-5p could be a biomarker of COPD severity. However, more about miR-106b-5p must be understood to elucidate any mechanism, as it has come up in several miRNA serum studies, including carcinogenesis.…”

Section: Biological Markers and The Evolution To Endotypic Therapymentioning

confidence: 99%

Precision medicine in COPD: where are we and where do we need to go?

2018

View full text Add to dashboard Cite

Chronic obstructive pulmonary disease (COPD) was the fourth leading cause of death worldwide in 2015. Current treatments for patients ease discomfort and help decrease disease progression; however, none improve lung function or change mortality. COPD is heterogeneous in its molecular and clinical presentation, making it difficult to understand disease aetiology and define robust therapeutic strategies. Given the complexity of the disease we propose a precision medicine approach to understanding and better treating COPD. It is possible that multiOMICs can be used as a tool to integrate data from multiple fields. Moreover, analysis of electronic medical records could aid in the treatment of patients and in the predictions of outcomes. The Precision Medicine Initiative created in 2015 has made precision medicine approaches to treat disease a reality; one of these diseases being COPD.

show abstract

Peripheral leukocyte microRNAs as novel biomarkers for COPD

Cited by 28 publications

References 59 publications

MicroRNAs as Potential Regulators of Immune Response Networks in Asthma and Chronic Obstructive Pulmonary Disease

MicroRNAs as Potential Regulators of Immune Response Networks in Asthma and Chronic Obstructive Pulmonary Disease

Circulating microRNA‐15b‐5p as a biomarker for asthma‐COPD overlap

Precision medicine in COPD: where are we and where do we need to go?

Contact Info

Product

Resources

About